RxDoctor Payments Data

Sydney Saxena, MD

Internal Medicine · Cincinnati, OHNPI 1972532810

Payments from drug & device makers

$21,408in general payments, 2019–2025

Across 228 payments — averaging $93.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$16K
  • AbbVie$1K
  • Pfizer$459
  • Lilly USA, LLC$344
  • Teva Pharmaceuticals USA, Inc.$278
  • GSK$257
  • plus $3K from 37 others

What the payments were for

  • Speaking & faculty fees$13,48063%
  • Travel & lodging$1,0425%
  • Food & beverage$6,87532%
  • Education$120%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,408 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$173,313
Medicare patients
365
Services billed
1,708

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban254$212,019
JardianceEmpagliflozin167$197,899
OzempicSemaglutide83$90,116
XareltoRivaroxaban73$87,019
JanuviaSitagliptin Phosphate88$79,217
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$46,398
FarxigaDapagliflozin Propanediol39$44,969
TrulicityDulaglutide46$42,909
CreonLipase/Protease/Amylase18$28,595
EntrestoSacubitril/Valsartan29$24,088
TradjentaLinagliptin27$23,222
LinzessLinaclotide14$18,617
Nurtec OdtRimegepant Sulfate14$17,339
Tresiba Flextouch U-100Insulin Degludec18$17,238
Breo ElliptaFluticasone/Vilanterol33$16,551

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$459$229,359268 claims
Boehringer IngelheimJardiance, Tradjenta$50$221,121194 claims
Novo NordiskOzempic$226$90,11683 claims
Johnson & JohnsonXarelto$15$87,01973 claims
MerckJanuvia$88$79,21788 claims
AstraZenecaFarxiga, Breztri Aerosphere, Lokelma$16,323$65,08869 claims
GSKTrelegy Ellipta, Breo Ellipta$257$62,94981 claims
AbbVieCreon, Linzess$1,006$47,21232 claims
Lilly USA, LLCTrulicity$344$42,90946 claims
NovartisEntresto$88$24,08829 claims
Astellas Pharma US IncMyrbetriq$25$10,46361 claims
Avanir Pharmaceuticals, Inc.Nuedexta$114$9,12112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →